Current filters:

gemcitabine Hcl

1 to 9 of 160 results

UK’s NICE issues draft guidance on suite of ovarian cancer drugs


Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

US FDA backs Abraxane for metastatic pancreatic cancer


US biotech firm Celgene (Nasdaq: CELG) said on Friday (September 6) that the US Food and Drug Administration…

AbraxaneBiotechnologyCelgenegemcitabine HclNorth AmericaOncologyRegulation

Celgene's Abraxane plus gemcitabine extends survival in pancreatic cancer patients


US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III clinical trial of Abraxane (nab-paclitaxel)…

AbraxaneBiotechnologyCelgenegemcitabine HclOncologyResearch

Amgen halts ganitumab study on little hope of success


USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, late yesterday revealed…

AmgenBiotechnologyganitumabgemcitabine HclOncologyResearch

Hospira gains US approval of solution version of gemcitabine injection


US generic injectable drug leader Hospira (NYSE: HSP) says the US Food and Drug Administration has approved…

Eli Lillygemcitabine HclGemzarGenericsHospiraNorth AmericaOncologyRegulation

Eli Lilly outlines innovation strategy, sets 2010 financial guidance, but disappoints Wall Street


At its annual meeting with the investment community yesterday, US drug major Eli Lilly outlined how its…

CymbaltaDuloxetine HclEvistaFinancialgemcitabine HclGemzarLillyOlanzapinePharmaceuticalRaloxifeneZyprexa

1 to 9 of 160 results

Back to top